Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence
The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
Swift elimination of undesirable cells is an important feature in tumour suppression and immunity. The tumour suppressor p53 and interferon-alpha and -beta (IFN-alpha/beta) are essential for the induction of apoptosis in cancerous cells and in antiviral immune responses, respectively, but little is known about their interrelationship. Here we show that transcription of the p53 gene is induced by IFN-alpha/beta, accompanied by an increase in p53 protein level. IFN-alpha/beta signalling itself does not activate p53; rather, it contributes to boosting p53 responses to stress signals. We show examples in which p53 gene induction by IFN-alpha/beta contributes to tumour suppression. Furthermore, we show that p53 is activated in virally infected cells to evoke an apoptotic response and that p53 is critical for antiviral defence of the host. Our study reveals a hitherto unrecognized link between p53 and IFN-alpha/beta in tumour suppression and antiviral immunity, which may have therapeutic implications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In response to senesce-inducing stimuli, senescent cells produce, in a cGAS-dependent manner, type I interferons that have pro-senescence and anti-proliferative activities.”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [273]
In the citing paper
“Indeed, β-interferons increase ROS production, leading to DNA damage and p53 activation [273,274].”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [273]
Citations
Cites
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
Darnell, J. E., Kerr, L. M., & Stark, G. R. (1994) · Science · doi:10.1126/science.8197455 · Cited by 6,080 · cited 1×
“2a ); ISRE is activated by the IFN-activated transcription factor ISGF3, a heterotrimeric complex consisting of a signal transducer and activator of transcription factor 1 (Stat1), Stat2 and interferon regulatory factor 9 (IRF-9”
BackgroundMice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649 · cited 1×
“Previous studies have shown that p53 -deficient mice show no sign of abnormality in T and B cells, and that they can mount adaptive immune responses normall”
ResultMdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · cited 1×
“We performed a pulse–chase experiment to examine whether the observed p53 protein induction is secondary to suppression of the p53 degradation pathway by IFN-β, typically the MDM2-mediated pathwa”
MethodPapillomaviruses and cancer: from basic studies to clinical application
zur Hausen, H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc798 · Cited by 4,024 · cited 1×
“Persistent infection with oncogenic HPV types represents a major risk factor for the development of cervical cancer, in which E6 is known to have a critical role (together with another oncoprotein, E7 (ref”
BackgroundDNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation
Bakkenist, C. J., & Kastan, M. B. (2003) · Nature · doi:10.1038/nature01368 · Cited by 3,466 · cited 1×
“We infer that, similar to DNA damage, ATM activation is caused by changes in the chromatin structure in virus-infected cell”
BackgroundRegulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“We performed a pulse–chase experiment to examine whether the observed p53 protein induction is secondary to suppression of the p53 degradation pathway by IFN-β, typically the MDM2-mediated pathwa”
MethodLive or let die: the cell's response to p53
Vousden, K. H., & Lu, X. (2002) · Nature Reviews Cancer · doi:10.1038/nrc864 · Cited by 3,192
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925 · cited 1×
“We also examined the effect of IFN-β on the DNA damage-induced apoptotic response of MEFs expressing the adenovirus E1A oncoprotein, as it is well known that this response is p53-dependent and critical for tumour suppressio”
BackgroundNoxa, a BH3-Only Member of the Bcl-2 Family and Candidate Mediator of p53-Induced Apoptosis
Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., Tokino, T., Taniguchi, T., & Tanaka, †. N. (2000) · Science · doi:10.1126/science.288.5468.1053 · Cited by 2,112
Self-citation
Research works printed but not linked: 1
- Vilcek, J. & Sen, G. S. in Fields Virology 3rd edn (eds Fields, D. M., Knipe, P. M. & Howley, P. M.) 375–399 (Lippincott-Raven, Philadelphia, 1996)
Cited by
Items 601–700 of 867
Makita, K., Hara, H., Sano, E., Okamoto, Y., Ochiai, Y., Harada, T., Ueda, T., Nakayama, T., Aizawa, S., & Yoshino, A. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4743 · Cited by 14
Guo, H.-R., Shen, S., Li, Y., Bi, R., Zhang, N.-N., Zheng, W., Deng, Y.-Y., Yang, Y., Yu, X., Wang, C.-X., et al. (2019) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1016/j.bbrc.2019.07.028 · Cited by 11
Medrano, R. F. V., Hunger, A., Catani, J. P. P., & Strauss, B. E. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1329072 · Cited by 14
Castoldi, L., Golim, M. D. A., Filho, O. G. R., Romagnoli, G. G., Ibañez, O. M., & Kaneno, R. (2006) · Immunology · doi:10.1111/j.1365-2567.2006.02513.x · Cited by 13
NPC Natural Product Communications
Khana, S. I., Hester, J. P., Tekwania, B. L., Midiwob, J. O., Muhammada, I., Jaina, S. K., Jacoba, M. R., Walkera, L. A., Rahmana, A. A., & Samoylenkoa, V. (2011) · Cited by 11
Antitumor activity of recombinant RGD-IFN-α2a-core fusion protein in vitro
Wen, Z., Jia, Q., Kang, X., Lou, Y., Zou, L., Yang, J., Gao, J., Han, L., & Li, X. (2016) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000421 · Cited by 10
Ye, C., Liu, S., Li, N., Zuo, S., Niu, Y., Lin, Q., Liang, H., Luo, X., & Fu, X. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02727-21 · Cited by 10
Longo, L. V. G., Hughes, T. L., McNeil-Laidley, B., Cottini, F., Hilinski, G., Merritt, E., & Benson, D. M. (2023) · Haematologica · doi:10.3324/haematol.2023.282838 · Cited by 13
Henry, B., Phillips, A. J., Sibley, L. D., & Rosenberg, A. (2024) · mBio · doi:10.1128/mbio.02124-24 · Cited by 12
KSHV manipulation of the cell cycle and programmed cell death pathways
Moore, P. S. (2007) · Cambridge University Press eBooks · doi:10.1017/cbo9780511545313.031 · Cited by 10
Wang, L., Wu, Z., Huang, Q., Huang, K., Qi, G., Wu, C., Mao, H., Xu, X., Wang, H., & Hu, C. (2017) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2017.08.019 · Cited by 12
Kim, J., Cho, M., Kim, K. I., Min, E., Lim, J.-W., & Hong, S. (2021) · Archives of Virology · doi:10.1007/s00705-021-04980-9 · Cited by 10
TP53 mutation-associated immune infiltration and a novel risk score model in HNSCC
Kong, W., Han, Y., Gu, H., Yang, H., & Zang, Y. (2022) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2022.101359 · Cited by 13
PML has a predictive role in tumor cell permissiveness to interferon-sensitive oncolytic viruses
Sobol, P. T., Hummel, J., Rodrigues, R., & Mossman, K. L. (2009) · Gene Therapy · doi:10.1038/gt.2009.68 · Cited by 10
Polson, A., Takahashi, P., & Reisman, D. (2010) · Cell Biology International · doi:10.1042/cbi20090401 · Cited by 11
“In addition to alterations in protein stability, it is generally accepted that regulation of the p53 protein levels is also correlated to how the gene is transcriptionally regulated (Takaoka et al., 2003).”
BackgroundGoto, H., Kariya, R., Kudo, E., Okuno, Y., Ueda, K., Katano, H., & Okada, S. (2017) · Oncogene · doi:10.1038/onc.2017.138 · Cited by 10
Yan, J., Yu, J., Wu, X., Xu, T., Yu, H., Dai, J., Ma, M., Tang, H., Xu, L., Chi, Z., et al. (2018) · Journal of Cancer · doi:10.7150/jca.24013 · Cited by 10
Rhabdoviruses, Antiviral Defense, and SUMO Pathway
Asmi, F. E., Brantis-de-Carvalho, C. E., Blondel, D., & Chelbi‐Alix, M. K. (2018) · Viruses · doi:10.3390/v10120686 · Cited by 10
Owczarz, M., Połosak, J., Domaszewska-Szostek, A., Kołodziej, P., Kuryłowicz, A., & Puzianowska‐Kuźnicka, M. (2020) · Epigenetics · doi:10.1080/15592294.2020.1780081 · Cited by 13
Are There More Human Cancer Viruses Left to Be Found?
Moore, P. S., & Chang, Y. (2024) · Annual Review of Virology · doi:10.1146/annurev-virology-111821-103721 · Cited by 11
Shimomura, S., & Nishiguchi, S. (2011) · Hepatology Research · doi:10.1111/j.1872-034x.2011.00889.x · Cited by 9
Roles of PAR1 and PAR2 in viral myocarditis
Mackman, N., & Antoniak, S. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.03.011 · Cited by 9
Lei, Y., Guo, P., Li, X., Zhang, Y., & Du, T. (2019) · BioMed Research International · doi:10.1155/2019/7267816 · Cited by 9
Park, J., Yoon, H., Jeong, Y., & Jang, K. L. (2022) · FEBS Letters · doi:10.1002/1873-3468.14461 · Cited by 9
Radiogenomics-Based Risk Prediction of Glioblastoma Multiforme with Clinical Relevance
Qian, X., Tan, H., Liu, X., Zhao, W., Chan, M. D., Kim, P., & Zhou, X. (2024) · Genes · doi:10.3390/genes15060718 · Cited by 9
“In particular, IRF9 is involved in a series of biological pathways directly or indirectly related to cell proliferation, apoptosis, and innate immunity [42–48] and has been identified as a potential biomarker for distinguishing PsP and TTP in our previous radiogenomics study [39].”
BackgroundNakano, N., Kawaoka, T., Aikata, H., Honda, F., Nakamura, Y., Morio, K., Hatooka, M., Fukuhara, T., Kobayashi, T., Hiramatsu, A., et al. (2016) · Hepatology Research · doi:10.1111/hepr.12698 · Cited by 9
Deng, X., Wei, J., Shi, Z., Yan, W., Wu, Z., Shao, D., Li, B., Liu, K., Wang, X., Qiu, Y., et al. (2016) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2016.07.002 · Cited by 9
Lieberman, R., Pan, J., Zhang, Q., & You, M. (2017) · Oncotarget · doi:10.18632/oncotarget.16371 · Cited by 9
Double-stranded RNA induces chicken T-cell lymphoma apoptosis by TRIF and NF-κB
Zou, H., Su, R., Ruan, J., Shao, H., Qian, K., Ye, J., Yao, Y., Nair, V., & Qin, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-07919-w · Cited by 10
Kimura, Y., Negishi, H., Matsuda, A., Endo, N., Hangai, S., Inoue, A., Nishio, J., Taniguchi, T., & Yanai, H. (2018) · Cancer Science · doi:10.1111/cas.13726 · Cited by 9
Self-citationRueschenbaum, S., Cai, C., Schmidt, M., Schwarzkopf, K. M., Dittmer, U., Zeuzem, S., Welsch, C., & Lange, C. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.581352 · Cited by 10
“Beyond their important antiviral features, IFNs show essential anti-proliferative and anti-tumor properties (21).”
BackgroundType I interferons: One stone to concurrently kill two birds, viral infections and cancers
Kumar, A., Khani, A. T., & Swaminathan, S. (2021) · Current Research in Virological Science · doi:10.1016/j.crviro.2021.100014 · Cited by 9
Forsbach, A., Müller, C., Montino, C., Kritzler, A., Nguyen, T. B., Weeratna, R. D., Jurk, M., & Vollmer, J. (2012) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2011.0091 · Cited by 9
Ctenopharyngodon idella p53 mediates between NF-κB and PKR at the transcriptional level
Huang, Q., Xie, D., Mao, H., Wang, H., Wu, Z., Huang, K., Wan, Y., Xu, Q., & Hu, C. (2017) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2017.08.012 · Cited by 9
Cunha, J. B., Leix, K., Sherman, E. J., Mirabelli, C., Frum, T., Zhang, C. J., Kennedy, A. A., Lauring, A. S., Tai, A. W., Sexton, J. Z., et al. (2023) · Journal of Virology · doi:10.1128/jvi.01276-23 · Cited by 9
IRF family transcription factors in type I interferon induction
Yanai, H., Mizutani, T., Inuzuka, T., Honda, K., Takaoka, A., & Taniguchi, T. (2005) · International Congress Series · doi:10.1016/j.ics.2005.09.010 · Cited by 8
Self-citationTakagi, M., Ohashi, K., Morimura, T., Sugimoto, C., & Onuma, M. (2006) · Leukemia Research · doi:10.1016/j.leukres.2005.12.009 · Cited by 8
The impact of p53 on the early stage replication of retrovirus
Kinnetz, M., Alghamdi, F., Racz, M. J., Hu, W., & Shi, B. (2017) · Virology Journal · doi:10.1186/s12985-017-0820-7 · Cited by 8
Kong, C., Chen, M., Fan, X., & Chen, X. (2020) · Journal of International Medical Research · doi:10.1177/0300060520943420 · Cited by 8
“As a tumor suppressor, IL-12 increases production of IFN-c, which increases p53 expression, contributing to tumor cell apoptosis.(34) Wang et al.”
BackgroundRegulation of immunological tolerance by the p53-inhibitor iASPP
Akama‐Garren, E. H., Miller, P., Carroll, T. M., Tellier, M., Sutendra, G., Buti, L., Zaborowska, J., Goldin, R. D., Slee, E. A., Szele, F. G., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05567-9 · Cited by 12
Chiang, C.-Y., Tu, H., Chen, Y., Chin, Y., Lai, T.-M., Chiu, H.-C., Nieh, S., & Fu, E. (2010) · Journal of Periodontal Research · doi:10.1111/j.1600-0765.2010.01312.x · Cited by 8
Impaired IFN- α Production and the Risk of Cancer Development
Uno, K., Hirosaki, M., Kakimi, K., Tominaga, M., Suginoshita, Y., Hasegawa, G., Fukui, M., Nakamura, N., Shirakawa, T., & Kíshida, T. (2007) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2007.0047 · Cited by 8
Sano, E., Tashiro, S., Tsumoto, K., & Ueda, T. (2014) · BioResearch open access · doi:10.1089/biores.2014.0052 · Cited by 8
Worthington, J., Spain, G., & Timms, J. F. (2017) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.061267 · Cited by 8
Matveeva, O. V., Kochneva, G. V., Zainutdinov, S. S., Ilyinskaya, G. V., & Chumakov, P. M. (2018) · Molecular Biology · doi:10.7868/s0026898418030023 · Cited by 9
Oncolytic Paramyxoviruses: Mechanism of Action, Preclinical and Clinical Studies
Matveeva, O. V., Kochneva, G. V., Zainutdinov, S. S., Ilyinskaya, G. V., & Chumakov, P. M. (2018) · Molecular Biology · doi:10.1134/s002689331803010x · Cited by 8
Interferon‐induced TRAIL‐independent cell death in DNase II−/− embryos
北原, 雄., Kawane, K., & Nagata, S. (2010) · European Journal of Immunology · doi:10.1002/eji.201040604 · Cited by 8
P53 and other Cell Cycle Regulators
Farid, N. R. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/1-4020-8107-3_8 · Cited by 8
Accurate estimation of pathway activity in single cells for clustering and differential analysis
Davis, D., Wizel, A., & Drier, Y. (2024) · Genome Research · doi:10.1101/gr.278431.123 · Cited by 12
“Prior research showed that viral infection upregulates TP53 by type 1 interferon signaling (Takaoka et al. 2003) and, on the other hand, that TP53 both activates the interferon pathway and promotes type 1 interferon release from cells undergoing viral infection (Muñoz-Fontela et al. 2008).”
BackgroundWhen Immunity Kills: The Lessons of SARS-CoV-2 Outbreak
Taoufik, Y., de Herve, M.-G. D. G., Corgnac, S., Dürrbach, A., & Mami‐Chouaib, F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.692598 · Cited by 7
“The signaling pathway of IFN-l in epithelial leads to the induction of a group of IFN-stimulated genes (ISGs), and the tumor suppressor p53, the latter limiting viral replication by enhancing IFN signaling and inducing cell cycle arrest of infected cells (34, 36).”
BackgroundTam, H. W., Hall, J. R., Messenger, Z. J., Jima, D. D., House, J. S., Linder, K. E., & Smart, R. C. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz012 · Cited by 7
Tu, H., Fu, E., Chen, Y., Wu, M., Cheng, L. ‐., & Yang, S. (2007) · Journal of Periodontal Research · doi:10.1111/j.1600-0765.2007.00991.x · Cited by 8
Umemoto, S., Haruta, M., Sakisaka, M., Ikeda, T., Tsukamoto, H., Komohara, Y., Takeya, M., Nishimura, Y., & Senju, S. (2019) · Cancer Science · doi:10.1111/cas.14144 · Cited by 7
Ishida, N., Oritani, K., Shiraga, M., Yoshida, H., Kawamoto, S.-I., Ujiie, H., Masaie, H., Ichii, M., Tomiyama, Y., & Kanakura, Y. (2005) · Experimental Hematology · doi:10.1016/j.exphem.2005.01.002 · Cited by 9
Li, S., Wang, Y., Zhao, H., Shao, Y., Liu, J., & Xing, M. (2018) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2018.08.017 · Cited by 7
Wang, C., Liu, W., Cao, X., Huang, Y., Wang, X., Xiao, K., Li, X., Zhang, D.-D., & Jiang, G. (2020) · Frontiers in Marine Science · doi:10.3389/fmars.2020.00286 · Cited by 7
“…functions, such as apoptosis (Yonish-Rouach et al., 1991; Chipuk and Green, 2004), cell cycle progression (Livingstone et al., 1992; Agarwal et al., 1995) and antiviral immunity (Takaoka et al., 2003; MunozFontela et al., 2008), by regulating relevant genes (Lane, 1992; Francis et al., 2007).”
BackgroundValle, P. R. D., Mendonça, S. A., Antunes, F., Hunger, A., Tamura, R. E., Zanatta, D. B., & Strauss, B. E. (2021) · Cancer Biology & Therapy · doi:10.1080/15384047.2021.1899784 · Cited by 7
Künzi, M. S., & Pitha, P. M. (2005) · Humana Press eBooks · doi:10.1385/1-59259-939-7:025 · Cited by 7
Synergy of Interferon-α and 5-Fluorouracil in Human Renal Cell Carcinoma Requires p53 Activity
Shang, D., Ito, N., Watanabe, J., Awakura, Y., Nishiyama, H., Kamoto, T., & Ogawa, O. (2007) · European Urology · doi:10.1016/j.eururo.2007.01.045 · Cited by 7
p53 at the crossroads of MPN treatment
Plo, I. (2014) · Blood · doi:10.1182/blood-2014-06-579623 · Cited by 7
Toll-like receptors that sense viral infection
Seya, T., Shingai, M., & Matsumoto, M. (2004) · Uirusu · doi:10.2222/jsv.54.1 · Cited by 7
Duensing, S. M., Moore, P. S., & Parsonnet, J. (2007) · Wiley eBooks · doi:10.1002/9780470025079.chap24.pub2 · Cited by 9
Transcriptional regulation of disease-relevant microglial activation programs
McQuade, A., Mishra, R., Hagan, V., Liang, W., Colias, P. J., Castillo, V. C., Gonzalez, B., Lubin, J. P., Haage, V. C., Marshe, V. S., et al. (2026) · Neuron · doi:10.1016/j.neuron.2026.07.001 · Cited by 8
The bidirectional p53–Wrap53β promoter is controlled by common cis- and trans-regulatory elements
Polson, A., & Reisman, D. (2014) · Gene · doi:10.1016/j.gene.2013.12.046 · Cited by 6
Antitumor effect of mIFN-λ3 in C57BL/6 mice model for papilloma tumors
Choobin, H., Bamdad, T., Soleimanjahi, H., & Nikoo, H. R. (2015) · Molecular Biology · doi:10.1134/s0026893315050064 · Cited by 6
Li, A. H., Park, S. Y., Li, P., Zhou, C., Kluz, T. S., Li, J., Costa, M., & Sun, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031783 · Cited by 7
“IFN α , the first immunotherapeutic drug approved by the FDA for cancer treatment, displayed multiple anti-tumor activities [92–94].”
BackgroundHe, Z., Yin, B.-K., Wang, K., Zhao, B., Chen, Y., Li, Z., & Chen, J. (2024) · Metabolic Brain Disease · doi:10.1007/s11011-024-01354-3 · Cited by 6
Role of Cytokines in Tumor Immunity and Immune Tolerance to Cancer
Murugaiyan, G. (2014) · Springer eBooks · doi:10.1007/978-3-662-44006-3_7 · Cited by 8
Immune alteration fends off AIDS
O’Connell, K. A., & Siliciano, R. F. (2008) · Nature Medicine · doi:10.1038/nm1008-1016 · Cited by 6
Crossing Paths in Human Renal Cell Carcinoma (hRCC)
Gallego, G. A., Villaamil, V. M., Grande, E., Caínzos, I. S., & Aparicio, L. A. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131012710 · Cited by 6
Exploiting Extracellular Vesicles Strategies to Modulate Cell Death and Inflammation in COVID-19
Bortot, B., Romani, A., Ricci, G., & Biffi, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.877422 · Cited by 6
“Of note, p53 is activated in virally infected cells to evoke an apoptotic response, and it is critical for the antiviral defence of the host (Takaoka et al., 2003).”
BackgroundChoobin, H., Bamdad, T., Soleimanjahi, H., & Nikoo, H. R. (2015) · Molecular Biology · doi:10.7868/s0026898415050067 · Cited by 6
Chida, J., Araki, H., & Maeda, Y. (2014) · Cancer Cell International · doi:10.1186/1475-2867-14-56 · Cited by 6
Conflicting Signals for Cancer Treatment
Sujobert, P., & Trautmann, A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1393 · Cited by 6
Özkan, A. D., Eskiler, G. G., Kaleli, S., & Sahin, E. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06953-2 · Cited by 6
Fujioka, N., Ariyasu, T., Arai, N., Ariyasu, H., Yamamoto, S., Tanimoto, T., Ikegami, H., Ikeda, M., Ohta, T., Fukuda, S., et al. (2006) · Biomedical Research · doi:10.2220/biomedres.27.219 · Cited by 6
Noguchi, R., Yoshiji, H., Ikenaka, Y., Kitade, M., Kaji, K., Yoshi, J., Yanase, K., Namisaki, T., Yamazaki, M., Tsujimoto, T., et al. (2008) · International Journal of Oncology · doi:10.3892/ijo.32.1.193 · Cited by 6
Cancer mutation profiles predict ICIs efficacy in patients with non-small cell lung cancer
Zhu, L., Ye, D., Lei, T., Wu, J., Wang, W., & Xu, B. (2022) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2022.9 · Cited by 6
Role of Cytokines in Tumor Immunity and Immune Tolerance to Cancer
Garo, L. P., & Murugaiyan, G. (2020) · Springer eBooks · doi:10.1007/978-3-030-30845-2_13 · Cited by 6
Gladwell, W., Yost, O. L., Li, H., Bell, W. J., Chen, S., Ward, J. M., Kleeberger, S. R., Resnick, M. A., & Menéndez, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316793 · Cited by 5
“In addition, IFNs bind to interferon-α / β receptors, causing the expression of hundreds of IFN-stimulated genes, including TP53 gene [15], that can then amplify the antiviral responses and establish functional loops to boost the immune response against RSV.”
BackgroundInfluentialŚwiątek-Kościelna, B., Kałużna, E. M., Januszkiewicz‐Lewandowska, D., Rembowska, J., Mozer‐Lisewska, I., Bereszyńska, I., Czubała, K., Dziechciowska, K., Wysocka-Leszczyńska, J., Barcińska, D., et al. (2015) · Viral Immunology · doi:10.1089/vim.2015.0026 · Cited by 5
Takayama, K., Furusyo, N., Ogawa, E., Ikezaki, H., Shimizu, M., Murata, M., & Hayashi, J. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i15.4696 · Cited by 5
“Interferon upregulate p53 gene transcription to halt the cell cycle, or to evoke an apoptotic response of cancerous cells [23,24] , and these antitumor effects probably play an important role in reducing the AFP level after interferon therapy [19] .”
BackgroundZhang, X., Xu, J., Marshall, B., Dong, Z., Smith, S. B., & Zhang, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158135 · Cited by 5
Bertram, H., Wilhelmi, S., Rajavel, A., Boelhauve, M., Wittmann, M., Ramzan, F., Schmitt, A. O., & Gültaş, M. (2023) · Biology · doi:10.3390/biology12070969 · Cited by 5
“In this context, the antiviral activities and apoptosis induction of IFN-α and IFN-β were extensively investigated [94,95].”
BackgroundEffect of anti-COVID-19 drugs on patients with cancer
Huang, W., Liu, W., Yu, T., Zhang, Z., Zhai, L., Huang, P., & Lü, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116214 · Cited by 6
Kotsarenko, K., Лыло, В. В., Macewicz, L. L., Бабенко, Л. А., Kornelyuk, A. I., Рубан, Т. А., & Лукаш, Л. Л. (2013) · Cytology and Genetics · doi:10.3103/s0095452713040087 · Cited by 5
Apoptosis Induction By Cytosolic RNA Helicases
Poeck, H. (2012) · Journal of Medical Microbiology & Diagnosis · doi:10.4172/2161-0703.1000117 · Cited by 5
Radiofrequency Ablation for Small Hepatocellular Carcinoma
Lau, W. Y., Zhang, Y., & Chen, M. (2015) · Springer eBooks · doi:10.1007/978-94-017-7258-7 · Cited by 5
Lu, L.-F., Zhou, X.-Y., Zhang, C., Li, Z.-C., Chen, D., Zhang, Y., & Li, S. (2020) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2020.05.023 · Cited by 5
Neurologic toxicity associated with interferon α therapy for renal cell carcinoma
Wada, Y., Kuwahara, T., Uyama, E., Nakanishi, J., TAKAHASHI, W., HONDA, J., Kikukawa, H., Jinnouchi, Y., & Ueda, S. (2006) · International Journal of Urology · doi:10.1111/j.1442-2042.2006.01410.x · Cited by 5
Relación entre asma e infecciones virales
Castro-Rodríguez, J. A. (2007) · Anales de Pediatría · doi:10.1016/s1695-4033(07)70578-7 · Cited by 8
Adenovirus E1B-55K regulates p53-dependent and -independent gene expression during infection
Seddar, L., von Stromberg, K., Bertzbach, L. D., Grundhoff, A. T., Dobner, T., & Ip, W.-H. (2025) · PLoS Pathogens · doi:10.1371/journal.ppat.1013622 · Cited by 5
“This is especially important as increasing evidence shows that p53 also has a vital role in innate immunity during viral infections [22,37,42]. p53 has been implicated in antiviral responses, partly through regulation of IRF9 and interactions with other interferon regulatory factors such as IRF7…”
Viral induction of Zac1b through TLR3- and IRF3-dependent pathways
Warzée, B., Mesnil, C., Hober, D., Caloone, D., Pirottin, D., Garigliany, M., Desmecht, D. J.-M., Drion, P.-V., Journot, L., Lekeux, P. M., et al. (2010) · Molecular Immunology · doi:10.1016/j.molimm.2010.09.004 · Cited by 4
“On the other hand, death of infected cells can also limit viral replication and dissemination, increasing host resistance to infection (Takaoka et al., 2003).”
BackgroundTanaka, A., Hayano, S., Nagata, M., Kosami, T., Wang, Z., & Kamioka, H. (2023) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2023.105797 · Cited by 5
Typhoid toxin of Salmonella Typhi elicits host antimicrobial response during acute typhoid fever
Srour, S., Brown, F., Sheffield, J. W., ElGhazaly, M., O’Connor, D., Gibani, M. M., Darton, T. C., Pollard, A. J., Collins, M. O., & Humphreys, D. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00347-8 · Cited by 4
“To provide more mechanistic insight, we investigated the connection between LYZ and DDRs. DNA damage due to typhoid toxin activates the type-1 interferon (IFN) response (Chen et al, 2024), and IFN can activate p53 expression (Takaoka et al, 2003).”
Wu, C., Casanova, R., Mairinger, F. D., & Soltermann, A. (2022) · Frontiers in Oncology · doi:10.2139/ssrn.4133126 · Cited by 5
May, K. F., Jinushi, M., & Dranoff, G. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394296-8.00008-7 · Cited by 4
Cancer Pathogenesis and DNA Sensing
Shen, Y. J., Lam, A. R., Ho, S. W. S., Koo, C. X., Bert, N. L., & Gasser, S. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-404732-7.00009-5 · Cited by 5
Yu, D., Zhang, S., Du, W., Zhang, J., ZongXing, F., Hao, H., Liú, Y., Zhao, X., Qin, T., & Zhu, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094444 · Cited by 4
Guo, S., Li, C., Dai, X.-M., Zhao, C., & Chang, W.-S. (2014) · Central European Journal of Immunology · doi:10.5114/ceji.2014.47728 · Cited by 4
Metadata
- Authors
- Takaoka, A., Hayakawa, S., Yanai, H., Stoiber, D., Negishi, H., Kikuchi, H., Sasaki, S., Imai, K., Shibue, T., Honda, K., & Taniguchi, T.
- Affiliations
- The University of Tokyo (JP)
- University of Vienna (AT)
- Sapporo Medical University (JP)
- Corresponding author
- Taniguchi, Tadatsugu
- ORCID
- Venue
- Nature
- Published
- 2003-07
- Volume
- 424
- Issue
- 6948
- Pages
- 516-523
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2119885778
- Cited by
- 847
- References
- 51
- Citations by year
- 2026: 13 · 2025: 18 · 2024: 20 · 2023: 25 · 2022: 22 · 2021: 32 · 2020: 41 · 2019: 40 · 2018: 21 · 2017: 38 · 2016: 50 · 2015: 44 · 2014: 40 · 2013: 46 · 2012: 38
- FWCI
- 20.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Boehringer Ingelheim Japan
- Senri Life Science Foundation
- Kanae Foundation for the Promotion of Medical Science
- Japan Society for the Promotion of Science
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- p53, type I interferon, interferon signaling, tumor suppression, antiviral defense, apoptosis, viral infection, cancer therapy
- MeSH terms
- Animals, Cell Transformation, Neoplastic, DNA-Binding Proteins, Humans, Mice, Inbred C57BL, Neoplasms, RNA, Messenger, Transcription Factors, Transcription, Genetic, Tumor Cells, Cultured, Vesicular stomatitis Indiana virus, Signal Transduction, Transcriptional Activation, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Interferon-alpha, Interferon-beta, Apoptosis, Response Elements, Interferon-Stimulated Gene Factor 3, Interferon-Stimulated Gene Factor 3, gamma Subunit, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.